Antiparasitic agents: new drugs on the horizon
Antiparasitic agents: new drugs on the horizon
复制标题
DOI：
10.1016/j.coph.2012.05.001
复制
发表时间：
2012-10-01
影响因子：
4
通讯作者：
Brun, Reto
中科院分区：
文献类型：
--
作者：
Maeser, Pascal;Wittlin, Sergio;Brun, Reto
由于耐药性和毒性问题正在危及现有的药物，因此对治疗恶性疟原虫和布鲁氏锥虫等热带寄生虫的新药的需求持续存在。在过去的12年里，旨在开发疟疾和昏睡病新药的公私合作伙伴关系提出了几种已进入临床试验的候选药物。它们是合成的过氧化氢OZ439和螺吲哚NITD609对恶性疟原虫的杀灭，非辛硝唑和恶唑醇SCYX-7158对布氏疟原虫的杀灭。另一类高化学治疗潜力的是二胺类化合物，它的新成员可以作为对抗锥虫和其他寄生虫的备份化合物。因此，治疗疟疾和昏睡病的新的治疗药物终于触手可及。
The need for new drugs against tropical parasites such as Plasmodium falciparum and Trypanosome brucei is persistent since problems with resistance and toxicity are jeopardizing the currently available medicines. Public-private partnerships aiming to develop new medicines for malaria and sleeping sickness have, over the past 12 years, brought forward several drug candidates that have entered clinical trials. These are the synthetic peroxide OZ439 and the spiroindolone NITD609 against P. falciparum, fexinidazole and the oxaborole SCYX-7158 against T. brucei. A further class of high chemotherapeutic potential are the diamidines, novel members of which may serve as back-up compounds against trypanosomes and other parasites. Thus, finally, new therapeutic agents against malaria and sleeping sickness are within reach.